Related Experiment Videos
[Multiple myeloma; treatment in the year 1998]
H M Lokhorst1, P Sonneveld, P W Wijermans
1Academisch Ziekenhuis, afd. Hematologie, Utrecht.
Nederlands Tijdschrift Voor Geneeskunde
|October 9, 1998
Summary
Autologous stem cell transplantation shows promise for multiple myeloma patients under 60 with responsive disease. Intensive treatments are being evaluated against conventional therapies in ongoing trials.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Context:
- Multiple myeloma treatment landscape.
- Intensive chemotherapy and stem cell transplantation are key areas of research.
- Evaluating treatment efficacy and patient outcomes.
Purpose:
- To review current studies on intensive chemotherapy and stem cell transplantation for multiple myeloma.
- To identify prognostic factors for autologous transplantation success.
- To compare autologous and allogeneic transplantation outcomes.
Summary:
- Autologous transplantation yields best results in younger, responsive multiple myeloma patients treated within a year.
- High beta-2-microglobulin and abnormal cytogenetics are unfavorable prognostic factors.
- Allogeneic transplantation outcomes are comparable to autologous, potentially due to patient selection and treatment-related mortality.
Impact:
- Provides insights into optimal patient selection for autologous stem cell transplantation.
- Highlights the need for further research into intensive treatment modalities.
- Informs future clinical trial design and treatment strategies for multiple myeloma.